Singapore: Amgen has received positive results from its global Phase 2 clinical trial of AMG 334, a fully human monoclonal antibody under investigation for the prevention of migraine.

The drug candidate inhibits the calcitonin gene-related peptide (CGRP) receptor that is believed to transmit signals that can cause incapacitating pain.

"Migraine is a complicated, underdiagnosed neurological condition that has significant impact on the everyday activities of those who live with it, and for the millions of people around the world who are affected by this disease, significant unmet therapeutic need persists," said Dr Sean E Harper, executive vice president, Research and Development, Amgen. "We are encouraged by these Phase 2 data, which further validate AMG 334 as a potential preventive treatment for episodic migraine."